Spain’s SME growth market asks for three things: a Registered Advisor, a liquidity provider and an admission document (DIIM). We help you decide whether it is the right route for you—or whether the continuous market or MARF suits you better—and get to the bell-ringing with your file complete.
Is your company ready to list? Free assessment
Tell us your size, sector and funding goal, and we will tell you which market fits and what you still need in order to be admitted.
Six legal fronts in going public: from choosing the route to the document the market will read, including getting your house in order first.
On BME Growth, the admission document (DIIM) supervised by the market is often enough; in other scenarios you need a prospectus approved by the CNMV. We draft and coordinate the document your transaction requires, with the 2024 Listing Act already on the map.
Before you present your company to the market, you need to audit it from the inside: corporate matters, contracts, litigation, accounts and corporate governance. Due diligence shows what to fix before the Registered Advisor or an investor finds it.
The listed real estate vehicle (Spanish REIT) is a market classic: BME Growth is the natural route for meeting the requirement that its shares be traded.
If you are looking for debt rather than equity, Spain’s alternative fixed-income market lets you issue bonds and commercial paper without opening up your shareholder base.
Regulated markets, MTFs and trading systems: understanding where you will be listed explains which obligations you will have afterwards.
Inside information, insider lists and market disclosures: the market abuse rules apply from the day you list.
Four projects that come to our firm with the same question and very different answers: which market is right for me?
"After several rounds, our investors want a liquidity horizon and we need more capital to grow. BME Growth would give us market access without the cost of listing on the continuous market."
"We are setting up a SOCIMI and its shares must be traded on a market. We want to understand the BME Growth admission process, the DIIM and the commitments we take on as a listed company."
"We do not want to be diluted or open up the board, but we do want to diversify beyond bank financing. We have heard about MARF for issuing bonds and need to know what it really requires."
"The investment bank is selling us the deal; what worries us is what comes after: periodic reporting, market abuse and corporate governance that can withstand public scrutiny."
Admissions that fail or drag on tend to share the same origin: the wrong route was chosen, or the company came to the process without its house in order.
Choosing a market for prestige rather than fit: forcing a leap to the continuous market when the company’s size and track record call for BME Growth (or straight debt on MARF) multiplies costs and can end in a failed, public transaction.
Underestimating internal preparation: accounts not properly audited, opaque shareholders’ agreements or litigation without provisions always surface in due diligence. Every late finding means lost time on the calendar and credibility burned with the Registered Advisor.
Thinking only about bell-ringing day: being listed is a permanent state, not an event: market disclosures, the market abuse regime and a working liquidity provider. Companies that do not budget for life as a listed company struggle in their first year.
| Route | Who it is for | Document requirement and key feature |
|---|---|---|
| BME Growth | Expanding SMEs and vehicles such as SOCIMIs that want to list with proportionate requirements. | In many cases, an admission document (DIIM) instead of a full prospectus; a Registered Advisor and a liquidity provider are required. |
| Continuous market | Larger companies ready for the full scrutiny of a regulated market. | As a general rule, a prospectus approved by the CNMV; maximum visibility and also maximum disclosure obligations. |
| MARF | Companies seeking debt financing (bonds, commercial paper) without opening up their capital. | The alternative fixed-income market’s own admission documentation; ownership is not diluted. |
We assess which route fits (BME Growth, the continuous market or MARF), prepare the company with an honest due diligence, coordinate the Registered Advisor and the liquidity provider, and draft the DIIM or the prospectus your transaction needs. No surprises halfway through.
BME Growth is Spain’s SME growth market: a segment designed so that growing companies can list with requirements proportionate to their size, without the full weight of a regulated market such as the continuous market.
Its typical issuers are expanding companies seeking capital and visibility, and vehicles such as SOCIMIs, for which this market has become the natural route to listing.
BME Growth requires every company to have a Registered Advisor: an entity approved by the market that assesses whether the company is fit for admission and supports it on an ongoing basis, checking that it meets its disclosure obligations.
It is a structural role, not an entry formality: the market relies on it for part of the supervision of its listed companies. Choosing it well—and coming to it with your house in order after a serious due diligence—shapes the whole process.
The liquidity provider is the intermediary hired by the company to act as counterparty in the trading of its shares, helping to ensure a reasonable price and volume for a mid-sized stock.
BME Growth requires one because liquidity is the Achilles’ heel of SME markets: without it, the share price loses its role as a benchmark and as an exit route for investors. The agreement with the provider and its monitoring are part of the ordinary life of a listed company.
The market admission document (DIIM) is the information document that BME Growth accepts, in many cases, instead of a full prospectus: it describes the company’s business, risks, accounts and governance so that investors can make an informed decision, under the market’s review and with the support of the Registered Advisor.
The prospectus, on the other hand, is the document approved by the CNMV under the EU prospectus regime, generally required for public offerings and admissions that fall outside the exempt cases. The exact boundary depends on the structure of each transaction; we analyze it on our CNMV prospectus page.
Generally speaking, when the transaction includes a public offering of securities that does not fall within the exemptions of the prospectus regime (by type of investor, amounts or other cases set out in the rules), the company needs a prospectus approved by the CNMV in addition to meeting the market’s requirements.
That is why the structure of the placement—who you offer to, how much and how—is designed with the document in mind from day one: the same admission may require a DIIM or a prospectus depending on how the investor fundraising is structured.
The 2024 Listing Act is the EU package that aims to make access to capital markets cheaper and simpler: simpler prospectuses and less burdensome requirements for listing and staying listed, with particular attention to SMEs and growth markets.
It is being rolled out gradually, so the prudent approach is to design each transaction with advice that is up to date at the time of launch: some simplifications may change which document you need and how much it costs to stay listed.
Look to debt instead of equity: MARF (Mercado Alternativo de Renta Fija, Spain’s alternative fixed-income market) lets mid-sized companies raise funding by issuing bonds and commercial paper to qualified investors, without diluting shareholders or exposing the share capital to the market.
It is the usual route to diversify beyond bank financing while keeping control. We explain the process, the documentation and the parties involved in bond issuance on MARF.
Being listed means entering a permanent regime: periodic and material disclosures to the market under its rules, keeping the Registered Advisor and the liquidity provider in place, and full subjection to the market abuse regime (handling of inside information, insider lists, notification of managers’ transactions).
Companies that budget for life as a listed company—team, procedures, calendar—enjoy the market; those that do not, suffer it. We cover the MAR regime in market abuse.
A BME Growth admission is won in the preparation: the right route, a clean house and a solid document. This is how we organize the process.
We test size, audited track record, funding needs and shareholders’ appetite against the three routes (BME Growth, the continuous market, MARF). Then comes internal due diligence: whatever the market is going to find, it is better that you find it first.
Selection and engagement of the Registered Advisor and the liquidity provider, structuring of the placement and drafting of the DIIM—or of the prospectus before the CNMV if the transaction requires it—with every material statement verified.
Processing with the market, the bell-ringing and the start of the permanent regime: a disclosure calendar, market abuse procedures and corporate governance that can stand up to public scrutiny.
If your transaction is debt, continue with bond issuance on MARF; if the document is the open question, start with the CNMV prospectus.
Nine terms you will hear in every meeting with banks, advisors and the market itself. Knowing them in advance saves you weeks.
The Spanish segment for growing companies: listing with proportionate requirements, a mandatory Registered Advisor and a liquidity provider.
An approved entity that assesses whether the company is fit for admission and continuously monitors that it meets its obligations.
An intermediary hired to provide liquidity for trading in the shares, sustaining a reasonable price and volume in mid-sized stocks.
BME Growth’s information document which, in many cases, replaces the full prospectus: the company’s business, risks, accounts and governance.
A document approved by the supervisor under the EU regime, generally required for public offerings outside the exempt cases.
A legislative package that simplifies prospectuses and the requirements for listing and staying listed, with a focus on SMEs and growth markets.
Listed real estate investment company (Spanish REIT): its regime requires its shares to be traded, and this market is its usual route.
Alternative fixed-income market: bonds and commercial paper for companies that want funding without diluting their shareholders.
The part of the share capital held by the public and available for trading. Without sufficient distribution, no market can work.
A business with a verifiable track record, audited accounts and a corporate structure with no surprises.
Audit reports, financial and legal due diligence and a clean, documented cap table.
Registered Advisor and liquidity provider engaged and operational from admission.
Signed agreements, appointments notified to the market and coordination procedures.
A DIIM or prospectus that is complete, accurate and consistent with the financial information and the real risks.
A document verified statement by statement, with supporting evidence on file and defined responsibilities.
Bodies, regulations and controls fit for a company with public investors.
Approved regulations, a justified board composition and internal reporting procedures.
Timely periodic reporting and compliance with the market abuse regime from day one.
Publication calendar, insider lists, inside information policy and MAR records.
Spotting them early is cheap; discovering them once the transaction has been announced is very expensive.
Going public rarely happens in isolation: it follows private rounds, runs alongside debt issues and leads to the discipline of a public company. These pages cover the transactions we usually work on alongside a BME Growth admission.
The earlier private path: agreements, valuations and a cap table that the market will later scrutinize closely.
Setting up and operating the listed real estate vehicle (Spanish REIT) whose natural destination is BME Growth.
The fixed-income alternative: institutional funding without dilution, with its own admission documentation.
The review that decides whether you are ready: numbers, contracts and risks seen the way the market will see them.
Complete the picture with the CNMV prospectus, the securities markets and financial instruments framework and, for life as a listed company, the market abuse regime and the Market Abuse Regulation (MAR).
Tell us about your listing project (equity or debt, timetable, amount) and we will send you a roadmap with routes and requirements.
BME Growth is Spain’s market for expanding SMEs: the route for growing companies to list with requirements proportionate to their size. Its architecture rests on three pieces: a Registered Advisor that assesses and supports the company on an ongoing basis, a liquidity provider that acts as counterparty in trading, and an admission document (DIIM) which, in many cases, replaces the full prospectus. Deciding whether it is your market—or whether your transaction calls for the continuous market or MARF—is the first important decision in any listing project, and it should be made with the 2024 Listing Act on the table.
Admission to BME Growth revolves around the Registered Advisor: an approved entity that examines the company’s suitability—business, accounts, governance—and monitors it while it is listed, acting as the market’s first filter. Added to this are the liquidity provider, hired to support trading in a mid-sized stock, and the package of information the company undertakes to publish. Arriving at that examination with your house in order is half the project: that is why prior financial due diligence is not optional; it is the difference between a smooth process and one full of nasty surprises.
In many cases, BME Growth allows admission with the market admission document (DIIM), prepared with the Registered Advisor and reviewed by the market itself. However, when the transaction includes a public offering of securities outside the exempt cases of the prospectus regime, a prospectus approved by the CNMV is required. The structure of the placement—type of investor, amounts, how funds are raised—determines which side of the line your transaction falls on, so the document and the placement are designed together. The details of the regime are on our CNMV prospectus page, and the 2024 Listing Act adds a push to simplify prospectuses and requirements, whose rollout should be checked when launching each transaction.
Not every company should go to BME Growth. Large companies ready for full scrutiny belong on the continuous market, with a CNMV prospectus as the general rule and the highest level of disclosure obligations. And companies seeking funding without opening up their capital have MARF: the alternative fixed-income market where they can issue bonds and commercial paper to qualified investors while keeping shareholder control. We describe the full playing field—regulated markets, multilateral trading facilities and their regulatory consequences—in securities markets and financial instruments.
The SOCIMI (Spanish REIT) is the textbook use case for BME Growth: its regime requires its shares to be traded, and this market offers a proportionate route to comply, which has filled the segment with real estate vehicles. Whatever your profile, remember that admission is not the finish line but a change of regime: periodic reporting to the market, keeping a Registered Advisor and a liquidity provider in place, and full subjection to the market abuse rules—inside information, insider lists, managers’ transactions. That ongoing discipline, which we cover in market abuse, is what you really need to budget for before ringing the bell.
Key legislation, linked to the official text:
Legislation and links reviewed in .